GSK 299423
Appearance
![]() | |
![]() | |
Names | |
---|---|
Preferred IUPAC name
6-Methoxy-4-[2-(4-{[(2H-[1,3]oxathiolo[5,4-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)ethyl]quinoline-3-carbonitrile | |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C25H27N5O2S | |
Molar mass | 461.58 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
![](http://up.wiki.x.io/wikipedia/commons/thumb/9/98/GSK_299423_with_Staphylococcus_aureus_DNA_gyrase_PDB_2XCS.png/220px-GSK_299423_with_Staphylococcus_aureus_DNA_gyrase_PDB_2XCS.png)
GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.[1][2][3]
No animal studies have been reported. No application has been made for human clinical trials.[citation needed]
References
[edit]- ^ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria[permanent dead link]," The Wall Street Journal, August 4, 2010
- ^ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' Archived 2010-08-16 at the Wayback Machine" Daily Finance, August 6, 2010
- ^ Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. 466 (7309): 935–40. Bibcode:2010Natur.466..935B. doi:10.1038/nature09197. PMID 20686482. S2CID 205221405. (primary source)